Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes

Data presented today at the 68th Scientific Sessions of the American Diabetes Association (ADA) demonstrated that once-daily liraglutide when taken alone produced statistically significant improvement in blood sugar (glucose) control in patients with type 2 diabetes, as compared to glimepiride, a widely used oral anti-diabetic drug (OAD).

In addition, liraglutide demonstrated the following benefits compared to glimepiride:

-Statistically significant reduction in body weight
-Statistically significant reduction in risk of hypoglycemia
-Statistically significant reduction in systolic blood pressure

In this 12-month study, 62% of patients treated with liraglutide who had not been previously treated with diabetes medications achieved an average reduction in blood sugar that brought them below the ADA target for HbA1c of 7%.

To view Multimedia News release go to, http://www.prnewswire.com/mnr/novonordisk/33424/